कृपया अन्य खोज का प्रयास करें
चिन्ह | एक्सचेंज | करेंसी | ||
---|---|---|---|---|
CSCI | टोरंटो | CAD | रियल टाइम | |
CSCI | NASDAQ | USD | रियल टाइम | |
0UGB | लंदन | CAD | रियल टाइम | |
ET8 | फ़्रंकफ़र्ट | EUR | देरी |
COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Alan H. DeCherney | - | - | Member of the Scientific Advisory Board |
Frans M. J. Debruyne | - | - | Member of the Scientific Advisory Board |
Dennis Turpin | - | 1999 | Independent Director |
Gilles R. Gagnon | 70 | 2007 | President, CEO & Director |
Ulf R. Rapp | - | - | Member of the Scientific Advisory Board |
Hartmut Michel | - | - | Member of the Scientific Advisory Board |
Daniel Douglas Von Hoff | 76 | 2005 | Member of the Scientific Advisory Board |
Klaus H. R. Diedrich | - | - | Member of the Scientific Advisory Board |
René Frydman | - | - | Member of the Scientific Advisory Board |
Marcel Verheij | - | - | Member of the Scientific Advisory Board |
Gerald Batist | - | - | Member of the Scientific Advisory Board |
Carolyn S. Egbert | - | 2012 | Independent Director |
Ulrich Kosciessa | - | 2024 | Independent Director |
Genevieve Foster | - | 2024 | Independent Director |
Ronald W. Miller | - | - | Independent Chairman |
William W. Li | 61 | 2024 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है